PURPOSE OF AWARD:
In honor of Robin Roberts, the V Foundation has established a research fund in her name, which will fund research related to cancer survivorship. There are 15.5 million U.S. cancer survivors, with that number expected to grow to 20.3 million by 2026. New research initiatives are urgently needed to reduce long-term complications of cancer treatment.

SCOPE OF RESEARCH: The V Foundation seeks to support research into the biological basis of and prevention of long-term adverse effects (such as premature death, second neoplasms, organ dysfunction (e.g., cardiac, pulmonary, gonadal, neuropathy), reduced growth and development, decreased fertility, impaired cognitive function) from both conventional therapies including XRT, surgery and targeted therapies, as well as newer immunotherapies. As immune-based therapies become more common, research is also needed regarding infectious disease complications.

Research areas may apply to adult and/or pediatric populations; to conventional therapies and/or immune-oncology therapies. Some research possibilities within this scope could include:

- **Determine risk stratification models** for selection of primary cancer therapy in order to balance efficacy with short and long-term toxicity. Such models may include clinical presentation, tumor features such as histology, stage and genomics and serum biomarkers. Biomarker research in both tumor and “host” are encouraged.
- Develop effective targeted intervention strategies to decrease the risk of long-term adverse effects. For example:
  - Investigate the causal pathway of selected chemotherapeutic agents that cause endothelial dysfunction and accelerate the atherosclerotic process.
  - Investigate the association between muscle mass loss and cardiometabolic dysfunction among cancer survivors.
- Investigate the role of genetic susceptibility in the development of non-malignant treatment-related adverse outcomes (in addition to subsequent malignancies) in cancer survivors.
- Research to advance early detection of recurrent or secondary cancers using innovative approaches.
- When applicable, mining of existing research databases (e.g., GDC, TCIA, TCGA) containing genomic data, clinical trial data or other for various translational research projects is encouraged to further research to prevent adverse treatment effects for oncology patients (adult or pediatric) post-treatment. This could lead to risk prediction models for adverse treatment effects that would include host and tumor characteristics.

**Note:** At this time we will **not** be funding psycho-social services type research such as quality of life, psychosocial well-being and dysfunction.
ELIGIBILITY CRITERIA:

Institution Eligibility:
- Only research institutions that received this invitation may submit a nominee for consideration. Other affiliates of the institution that did not receive the email are not eligible to nominate an applicant.
- Institutions must be non-profit research institutions in the US or Canada.

Applicant Eligibility:
The nominated applicant must lead the research team. The applicant must meet all of the following criteria to be eligible to submit an application:
- The nominee must be nominated by their Cancer Center Director if the research institution is a cancer center. If the research institution is not a cancer center, then the provost, dean or other senior research administrative official who is responsible for the internal nominee selection process may make the nomination. We do not review unsolicited applications.
- Applicant must be employed at a non-profit research institution (e.g. 501c3, Section 170).
- By the Due Date of the Application, applicants who will lead this research team must have all the following: Be scientists who hold a tenure-track faculty position at their cancer research institution. Non-promotable, adjunct, affiliated, temporary, part-time or acting faculty positions are not eligible for nomination to lead the research team. Applicants from US institutions must be either US Citizens or have a legal permit to work in the USA (either temporary or permanent).

GRANT SIZE AND DURATION: The Award is a three-year grant of $200,000 per year. A maximum of 10% indirect costs (within the award amount) are supported in the Award. NIH salary caps are observed.

NEXT STEPS TO NOMINATE YOUR APPLICANT:
Complete the attached Nomination Information Form and email to nominations@jimmyv.org by August 15, 2018. The nomination form includes the signature of the Cancer Center Director (or similar high ranking research official if there is no cancer center director) who is responsible for the nomination and ensuring that the candidate meets all eligibility requirements. After we receive your Nominee Information Form, we will issue an invitation to your applicant who can then submit their application on-line.

IMPORTANT DATES:
Nomination Due Date: by 5:00 PM Eastern Time on August 15, 2018.
Translational Application Due Date: by 5:00 PM Eastern Time on September 17, 2018.
Grant start dates: December 2018.

If you have any questions about the nomination process, please contact us at grants@jimmyv.org for assistance. We are delighted to extend this invitation and look forward to receiving your nominations.

Best Wishes,

Carole

Carole C. Wegner, PhD, HCLD
Vice President, Research and Grants Administration
the V Foundation for Cancer Research
14600 Weston Parkway
Cary, NC 27513
919-443-3577
jimmyv.org
VICTORY OVER CANCER